Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 7/20 | 0.37 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.37 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | IMPDH2 | P12268 | 6/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.34 |
| ▸ | KRAS | P01116 | 2/20 | 0.34 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.33 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.33 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.33 |
| ▸ | TGM2 | P21980 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5694206 | 0.92 | P2RY12 (0.36) | P2RY6NT5EIMPDH2TAS1R3TAS1R1 | |
| SCHEMBL5694309 | 0.92 | P2RY6 (0.35) | P2RY6P2RY14NT5EIMPDH2TAS1R3 | |
| SCHEMBL5694292 | 0.91 | IMPDH2 (0.39) | NT5EIMPDH2TAS1R3TAS1R1KRAS | |
| SCHEMBL5908148 | 0.86 | POLB (0.35) | P2RY6P2RY14NT5EIMPDH2TAS1R3 | |
| SCHEMBL5908143 | 0.86 | TAS1R3 (0.38) | P2RY6NT5EIMPDH2TAS1R3TAS1R1 | |
| SCHEMBL5694266 | 0.84 | P2RY12 (0.35) | P2RY6IMPDH2TAS1R3TAS1R1KRAS | |
| SCHEMBL5694286 | 0.82 | IMPDH2 (0.36) | NT5EIMPDH2TAS1R3TAS1R1KRAS | |
| SCHEMBL5908163 | 0.79 | TERT (0.35) | P2RY6P2RY2P2RY4 | |
| SCHEMBL5694259 | 0.78 | P2RY6 (0.45) | P2RY6P2RY14NT5EP2RY2P2RY4 | |
| SCHEMBL5694277 | 0.78 | TAS1R3 (0.36) | IMPDH2TAS1R3TAS1R1KRASIMPDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | MITSUI CHEMICALS, INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1645561-A1 | METHOD OF SYNTHESIZING CYCLIC BISDINUCLEOSIDE | Mitsui Chemicals, Inc. (JP) | 2006-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | NSUN2, POLR2H, POLB | P2RY6 4021/4885P2RY14 4619/4885NT5E 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.